Insomnia Market : Size, Share, Trends & Forecast 2036

Market Overview:

Why the Global Insomnia Market Represents One of the Most Consequential Healthcare Opportunities of the Coming Decade

The global insomnia market was valued at approximately USD 5.92 billion in 2026 and is projected to reach USD 11.28 billion by 2035, advancing at a compound annual growth rate of 7.4% across the forecast period. This trajectory positions insomnia treatment as one of the fastest-scaling segments within the broader sleep medicine and neurological health ecosystem. The sustained expansion reflects a convergence of rising disease burden, intensifying clinical recognition, and a generational shift in how both patients and healthcare systems approach sleep as a pillar of preventive health rather than a secondary concern.

Insomnia, defined clinically as the persistent difficulty in initiating or maintaining sleep, or experiencing non-restorative sleep despite adequate opportunity, affects an estimated 10 to 30 percent of the global adult population in its chronic form and up to 50 percent of adults episodically. The condition is no longer regarded solely as a symptom of other disorders but increasingly recognised as an independent chronic disease with significant comorbid associations to cardiovascular disease, depression, anxiety, metabolic syndrome, type 2 diabetes, and neurodegenerative conditions. This reclassification has profound commercial implications, expanding both the addressable patient population and the range of therapeutic modalities qualifying for reimbursement.

The macro forces reshaping the market over the 2021 to 2025 historical period include the global mental health crisis amplified by the COVID-19 pandemic, the proliferation of wearable health technology enabling continuous sleep tracking at scale, and growing prescriber and patient acceptance of cognitive behavioural therapy for insomnia (CBT-I) as the first-line clinical standard. Post-pandemic normalisation has not reversed the rise in insomnia prevalence. Instead, the structural factors that drove sleep disorders during crisis conditions   remote work disruption of circadian rhythms, social isolation, increased screen exposure, and health anxiety   have crystallised into persistent behavioural patterns affecting tens of millions of adults globally.

The period from 2026 to 2035 is particularly consequential for this market because it represents the convergence of three major disruptions: the maturation of prescription digital therapeutics (PDT) as a regulated treatment category, the commercial launch of a new generation of pharmacological agents including dual orexin receptor antagonists (DORAs), and the emergence of AI-driven personalised sleep programmes that learn and adapt to individual patient profiles. Collectively, these developments are shifting the insomnia treatment paradigm from reactive prescription management toward proactive, integrated sleep health management   a transition that creates enormous opportunities for pharmaceutical companies, digital health developers, wearable technology providers, and clinical service operators alike.

Geopolitical and macroeconomic forces are also shaping market dynamics. Supply chain vulnerabilities exposed during the pandemic have prompted pharmaceutical manufacturers to regionalize active pharmaceutical ingredient (API) sourcing for sleep medications, with particular implications for generic drug availability and pricing in emerging markets. Trade tariff dynamics affecting medical device components continue to influence the cost structure of wearable sleep monitoring hardware, creating regional price disparities that affect adoption rates. In North America, the continued evolution of pharmacy benefit management and the push toward value-based care models are accelerating the integration of digital sleep therapeutics into employer health benefit plans, a distribution pathway that did not meaningfully exist before 2021.

The relationship between the insomnia market and broader healthcare megatrends is multidimensional. The global movement toward preventive and personalised medicine is driving investment in sleep health as a modifiable risk factor across conditions from cardiovascular disease to obesity. The digitisation of healthcare delivery, accelerated by telehealth adoption during the pandemic, has permanently lowered the barrier to accessing sleep therapy   particularly for CBT-I, which historically required in-person therapist sessions and is now available through FDA-cleared digital platforms. The ageing of the global population, with the over-65 demographic representing the highest-prevalence insomnia cohort globally, guarantees sustained organic demand growth across all treatment modalities through the forecast horizon.

Key Trends Reshaping the Insomnia Market Landscape Through 2035

• Rise of DORA-Based Therapies – Advanced insomnia drugs are improving treatment effectiveness and safety.
• Growth of Digital Therapeutics (DTx) – App-based CBT-I and digital sleep solutions are gaining widespread adoption.
• AI-Powered Sleep Management – AI-driven sleep coaching and personalized treatment plans are transforming patient care.
• Wearable Sleep Monitoring Expansion – Smartwatches and sleep trackers are enhancing real-time sleep analysis.
• Increasing Focus on Preventive Sleep Health – Employers and healthcare providers are investing more in sleep wellness programs.

The Commercial Emergence of Dual Orexin Receptor Antagonists Is Redefining the Standard of Pharmacological Care. The approval and commercial rollout of dual orexin receptor antagonists, including suvorexant (Merck’s Belsomra), lemborexant (Eisai and Vanda’s Dayvigo), and most recently daridorexant (Idorsia’s Quviviq, approved in Europe in 2022 and expanding globally through 2024 and 2025), marks the most significant pharmacological advance in insomnia treatment in two decades. Unlike benzodiazepines and Z-drugs, which broadly suppress central nervous system activity, DORAs act selectively on the orexin neurotransmitter pathway that maintains wakefulness, producing sleep onset without the dependency risks, next-morning impairment, or tolerance accumulation associated with older drug classes. The prescriber transition toward DORAs has accelerated since the European Medicines Agency approved daridorexant for adults with 6-month follow-up data demonstrating sustained efficacy without significant abuse potential. This class is reshaping the insomnia treatment algorithm and generating premium-priced prescription volume that is expanding total market revenue significantly above generic drug pricing baselines.

Prescription Digital Therapeutics Are Achieving Regulatory Parity With Pharmaceutical Treatments. The FDA’s clearance of Somryst (formerly by Pear Therapeutics) as a prescription digital therapeutic for chronic insomnia, and the FDA Breakthrough Device designation awarded to Big Health’s Sleepio platform, established a regulatory framework legitimising app-delivered CBT-I as a clinically valid, prescribable treatment. By 2025, several major U.S. employer health plans had incorporated Sleepio into their standard benefit packages, and the Veterans Health Administration had deployed digital CBT-I tools to address the high insomnia prevalence in the veteran population. This trend is fundamentally changing the competitive landscape by introducing a new category of treatment providers   technology companies   into a market historically dominated by pharmaceutical manufacturers and clinical service organisations. The DTx segment is forecast to grow at the highest CAGR of any treatment category through 2035, driven by scalability, lower per-episode cost compared to pharmacological intervention, and the absence of drug interaction risks.

Wearable-Integrated Sleep Monitoring Is Creating a New Ecosystem of Preventive Insomnia Management. Consumer-grade wearable devices from Oura Health (Oura Ring 4, launched 2024), Apple Watch sleep staging features, Garmin’s Body Battery sleep tracking, and Withings’ ScanWatch have moved from step-counting novelties to clinically informative sleep monitoring tools. In 2024, Oura announced a research partnership with UCSF to validate Oura Ring sleep data against polysomnography, a development that, if successful, could enable wearable sleep data to inform clinical diagnosis and treatment monitoring for insomnia at scale. This trend is creating a data-rich, consumer-engaged patient population that arrives at clinical consultations with months of personal sleep history   changing how clinicians diagnose and monitor treatment response, and creating commercial opportunities for platforms that can aggregate and interpret wearable sleep data within regulated healthcare workflows.

Employer Wellness Programmes Are Establishing Sleep Health as a Corporate Health Investment Priority. The quantification of insomnia’s economic burden   reduced productivity, increased absenteeism, higher workplace accident rates, and elevated comorbid healthcare costs   has driven major employers to treat sleep health as a material business risk requiring active management. A 2023 analysis published in the Journal of Occupational and Environmental Medicine estimated that insomnia costs U.S. employers approximately USD 63 billion annually in lost productivity alone. In response, companies including Amazon, JPMorgan Chase, and several major technology employers have added digital sleep therapy coverage and sleep health coaching to their employee assistance programs. This employer channel represents a structurally new distribution pathway for insomnia treatments that bypasses the traditional primary care referral chain, significantly expanding the addressable market for digital and non-pharmacological therapies.

What Is Driving Growth and What Is Holding It Back   Drivers, Restraints, and Opportunities

Market Drivers That Are Sustaining the 7.4% CAGR Through 2035

Escalating Global Insomnia Prevalence Is Expanding the Core Patient Population. The World Health Organization estimates that insomnia affects between 10 and 30 percent of the global adult population in clinically significant form, with prevalence rising sharply in populations over 60, among individuals with comorbid psychiatric disorders, and in working populations exposed to shift work or high-stress environments. The post-pandemic period has produced a documented increase in insomnia complaints across multiple national healthcare systems, with NHS England reporting a 20% increase in sleep disorder referrals between 2021 and 2024. This expanding patient base directly drives demand for both pharmacological and non-pharmacological treatments and supports increased healthcare system investment in sleep medicine capacity.

Regulatory Approvals for Novel Pharmacological Agents Are Expanding the Premium Prescription Market. The approval of daridorexant (Quviviq) by the EMA in April 2022 for the European market, followed by commercial launches in Germany, the UK, and Switzerland, and ongoing regulatory submissions in Asia-Pacific markets, is generating a new revenue layer of premium-priced DORA prescriptions. Idorsia’s Quviviq achieved rapid uptake in Germany following its January 2023 commercial launch, with prescriptions growing at over 40% quarter-on-quarter through 2024. The ongoing clinical pipeline includes next-generation orexin modulators and selective melatonin receptor agonists, suggesting continued regulatory-driven market expansion through the forecast horizon.

Rising Mental Health Awareness Is Normalising Help-Seeking Behaviour for Sleep Disorders. Destigmatisation campaigns from organisations including the American Academy of Sleep Medicine (AASM), the European Sleep Research Society, and national public health agencies in Australia and Canada have substantially reduced the cultural reluctance to seek treatment for insomnia. Telehealth platforms operating sleep medicine consultations   including Teladoc, Hims and Hers, and MDLive   have dramatically lowered the friction of initial consultation, enabling millions of patients who would previously have self-managed with OTC products to access clinical evaluation and prescription treatment. This increased care-seeking behaviour is converting a large population of previously untreated individuals into active treatment consumers.

Employer-Sponsored Digital Sleep Therapy Coverage Is Opening a New High-Volume Distribution Channel. Integrated employer health benefit plans that cover digital CBT-I platforms such as Sleepio and Somryst provide access to millions of working-age adults through their existing health benefits infrastructure without requiring primary care referral. This channel is particularly significant for the digital therapeutics segment, as it bypasses the traditional prescriber adoption hurdle. Major health insurance payors including Cigna, Aetna, and Optum have announced coverage expansions for digital sleep therapeutics between 2023 and 2025, reflecting the evidenced cost savings from reducing hypnotic drug prescribing and comorbid mental health treatment.

Government-Backed Sleep Health Initiatives Are Driving Structural Investment in Insomnia Infrastructure. The U.S. National Institutes of Health’s sustained funding for sleep research   exceeding USD 450 million annually as of 2024   is generating clinical evidence that supports treatment guideline updates, which in turn drive prescribing behaviour and reimbursement policy. The UK’s NHS Long Term Plan, published in 2019 and operationalised through 2024, includes sleep health as an explicit component of mental health service expansion, driving commissioning of CBT-I services across integrated care systems. Japan’s Ministry of Health Labour and Welfare updated its insomnia treatment guidelines in 2023 to recommend DORAs as preferred agents over benzodiazepines, directly reshaping the prescription market in the world’s third-largest pharmaceutical economy.

Ageing Global Demographics Are Guaranteeing Long-Term Organic Demand Growth. The United Nations projects that the global population aged 65 and over will reach 1.6 billion by 2035, representing the largest and fastest-growing insomnia-prevalence cohort worldwide. Age-related changes in sleep architecture   reduced slow-wave sleep, advanced sleep phase, increased sleep fragmentation   are clinically established and do not resolve without intervention. This demographic megatrend provides a structural floor beneath demand for all insomnia treatment modalities, with particular implications for the long-term care and homecare segments where access to clinical sleep medicine services has historically been limited.

Digital Health Investment Is Accelerating Insomnia Technology Platform Development. Global venture capital investment in sleep health technology exceeded USD 1.2 billion between 2022 and 2025, funding the development and commercial scaling of AI-driven sleep coaching platforms, clinical-grade home sleep testing devices, and personalised digital CBT-I tools. This investment surge is driving product innovation at a pace that exceeds the pharmaceutical development cycle, continuously introducing new treatment modalities that expand the total addressable market and attract non-traditional patients who prefer technology-based interventions over pharmacological treatment.

Market Restraints That Are Constraining Full Growth Potential

High Prescription Drug Costs and Inconsistent Reimbursement Coverage Are Limiting Patient Access. Premium-priced DORA medications carry monthly costs ranging from USD 280 to USD 450 in the United States without insurance coverage, creating a significant access barrier for the substantial portion of the population with high-deductible health plans or no prescription drug coverage. In emerging markets, reimbursement pathways for novel sleep medications are either non-existent or involve lengthy negotiation processes that can delay commercial launch by three to five years post-regulatory approval. This cost and access barrier is constraining the conversion of clinically identified insomnia patients into treated, revenue-generating consumers for premium product segments.

Lingering Stigma Around Sleep Disorders as a Medical Condition Is Suppressing Diagnosis Rates. Despite progress in mental health awareness, a substantial proportion of insomnia sufferers continue to perceive their condition as a character weakness or lifestyle problem rather than a treatable medical disorder requiring clinical intervention. Market research data suggests that fewer than 30 percent of individuals meeting clinical criteria for chronic insomnia ever present to a healthcare provider with a primary complaint of insomnia, representing a massive pool of untreated patients whose conversion to formal treatment would substantially expand market volume but requires continued public health investment to realise.

Concerns Regarding Long-Term Pharmacological Safety and Dependency Risk Are Limiting Prescription Duration. Even among the newer DORA drug class, clinical guidelines in several major markets including Germany and the United States recommend limiting continuous prescription duration to four weeks for initial treatment episodes, reflecting residual caution about long-term pharmacological sleep intervention despite the favourable safety profiles of modern agents. This prescriber conservatism creates gaps in treatment continuity that reduce the revenue-per-patient lifetime value for pharmaceutical manufacturers and push patients toward self-managed OTC alternatives, which carry lower margins for the market overall.

Fragmented Digital Health Reimbursement Pathways Are Slowing DTx Commercial Adoption. Despite FDA clearance and strong clinical evidence, prescription digital therapeutics for insomnia face reimbursement challenges that are slowing commercial scaling. The absence of a unified payor coding and billing framework for software-as-a-medical-device products in the United States, combined with the requirement for prescriber engagement in a market where primary care physicians have limited training in digital health tools, creates implementation friction that constrains the DTx segment’s growth relative to its clinical promise.

Shortage of Trained Sleep Medicine Specialists Is Constraining Diagnosis and Specialised Treatment. The American Academy of Sleep Medicine estimates that the United States faces a shortage of over 5,000 board-certified sleep medicine specialists, creating multi-month wait times for polysomnography and specialist consultation in many markets. This bottleneck limits the rate at which complex or treatment-resistant insomnia cases can be accurately diagnosed and appropriately managed, creating an unmet clinical need that is partially but not fully addressed by digital therapeutics and primary care prescribing expansion.

Strategic Opportunities Creating Premium Value for Market Entrants and Investors

The Untreated Insomnia Population in Emerging Markets Represents a Commercially Underexploited Opportunity of Substantial Scale. Asia-Pacific markets including India, Indonesia, Vietnam, and the Philippines collectively host hundreds of millions of adults with clinically significant insomnia who have never accessed formal treatment due to limited specialist availability, cultural stigma, and the absence of affordable pharmacological options. The rapid expansion of telehealth infrastructure in these markets, combined with growing middle-class healthcare expenditure, is creating the conditions for scalable, technology-mediated insomnia treatment delivery at accessible price points. Digital health platforms that can deliver validated CBT-I content through mobile applications, calibrated to local languages and cultural contexts, are positioned to capture this market before traditional pharmaceutical distribution infrastructure reaches scale.

Comorbid Insomnia Treatment in Oncology and Psychiatric Care Represents a High-Value Clinical Niche. Insomnia affects between 40 and 60 percent of cancer patients and up to 90 percent of patients with major depressive disorder, yet the treatment of sleep disturbance in these populations is systematically underaddressed within the primary disease management framework. Pharmaceutical companies and digital health providers that develop insomnia treatment programmes specifically validated for comorbid populations   supported by clinical data from oncology and psychiatric patient cohorts   can access reimbursement pathways through disease-specific care bundles rather than competing in the general chronic insomnia market, potentially commanding premium pricing justified by comorbidity management value.

AI-Personalised Sleep Coaching Platforms Are Creating a New Consumer Health Category With Subscription Economics. The integration of large language models and machine learning sleep pattern analysis into consumer sleep apps is enabling the delivery of genuinely personalised sleep improvement programmes at a scale that was previously only possible through one-to-one clinical therapy. Platforms that can demonstrate measurable, sustained sleep improvement outcomes through AI-driven coaching   validated by continuous wearable data rather than self-report   are positioned to establish a premium subscription category that monetises the large population of insomnia sufferers who prefer consumer-channel interventions over formal clinical treatment. This category combines the scalability of software with the clinical credibility of evidence-based CBT-I methodology, representing a fundamentally new commercial model for insomnia care.

How the Insomnia Market Divides   Full Segmentation Analysis

Segmentation Tables   By Type, Application, End User, and Region

The following tables provide a comprehensive breakdown of all primary and sub-segments across the global insomnia market, covering treatment type, insomnia classification, application, end user, distribution channel, and regional geography.

By Treatment Type   Pharmacological Versus Non-Pharmacological and Digital Modalities

The pharmacological segment retains market leadership in 2026, accounting for approximately 58% of total global insomnia market revenue, driven by the commercial scaling of DORA medications in North America and Europe and the continued high-volume prescribing of generic zolpidem and eszopiclone in price-sensitive markets. Within the pharmacological category, non-benzodiazepine receptor agonists   the Z-drugs including zolpidem, zaleplon, and eszopiclone   represent the largest revenue sub-segment by prescription volume, while the DORA class is generating the fastest revenue growth due to premium pricing and rapidly expanding prescriber adoption. Melatonin receptor agonists, represented primarily by ramelteon in the United States and prolonged-release melatonin in Europe, occupy a growing niche in elderly patients and those seeking non-dependency-forming pharmacological options.

The non-pharmacological segment, encompassing cognitive behavioural therapy for insomnia (CBT-I) delivered through clinical services, is growing steadily but faces capacity constraints from the shortage of trained CBT-I practitioners in most markets. The clinical service delivery model for CBT-I is increasingly being augmented   and in some cases replaced   by the digital therapeutics segment, which delivers validated CBT-I protocols through regulated software platforms at scale without per-session therapist cost. The digital therapeutics segment, while still representing less than 10% of total market revenue in 2026, is forecast to grow at the highest CAGR of any treatment category   exceeding 22% annually through 2030   driven by reimbursement expansion, employer health plan integration, and continued clinical evidence generation supporting digital CBT-I equivalence to in-person therapy.

By Type of Insomnia   Chronic Conditions Drive the Largest Revenue Share

Chronic insomnia, defined as the persistent difficulty with sleep occurring at least three nights per week for a period of three months or longer, represents the dominant disease category and the primary driver of specialist referral, prescription treatment, and digital therapeutic adoption. Chronic insomnia management accounts for approximately 65% of total insomnia market revenue in 2026, reflecting both the higher treatment intensity required for persistent cases and the substantially greater healthcare system costs associated with chronic sleep disorder management compared to acute episodic presentations. Comorbid insomnia   occurring in the context of psychiatric disorders, chronic pain, cancer, or cardiovascular disease   is an increasingly recognised and commercially significant sub-category, as healthcare systems move toward integrated management of sleep disturbance within the primary disease treatment pathway rather than addressing it only after the primary condition has been stabilised.

By Application   Chronic Insomnia Management Dominates but Emerging Applications Are Growing

Chronic insomnia management constitutes the leading application segment globally, driven by the scale of the chronic insomnia patient population, the treatment intensity of this group, and the growing sophistication of multi-modal treatment protocols combining pharmacological, CBT-I, and digital therapeutic components. Shift work sleep disorder (SWSD) represents a fast-growing application segment as awareness of the health and safety implications of shift-work-related sleep disruption drives occupational health investment, particularly in healthcare, transportation, and manufacturing sectors. Jet lag treatment, while smaller in absolute market scale, benefits from the recovery of international air travel to and beyond pre-pandemic levels, supporting demand for melatonin agonist medications and chronobiotic supplements among frequent international travellers.

By Distribution Channel   E-Commerce and Direct-to-Patient Channels Are Gaining Share Rapidly

Hospital and retail pharmacies collectively represent the dominant distribution channel for insomnia medications in 2026, with hospital pharmacy distribution particularly important for inpatient and specialist-initiated prescription medicines. However, the fastest-growing distribution channel is the combination of online pharmacy and direct-to-patient digital therapeutics subscription models, which collectively are growing at rates exceeding 18% annually. The online pharmacy channel benefits from the normalisation of telemedicine consultations that generate digital prescriptions redeemable online, while direct-to-patient DTx subscription models bypass the traditional pharmacy distribution chain entirely, delivering software-based therapy directly to the patient’s smartphone. This channel shift has significant implications for pharmaceutical manufacturer and retailer strategy, as pricing transparency and consumer switching behaviour in the online channel are fundamentally different from the traditional pharmacy environment.

Where in the World the Insomnia Market Is Growing   Regional Analysis Across All Five Geographies

North America Commands the Largest Share of Global Revenue and Will Sustain Market Leadership Through 2035

North America represents the dominant regional market for insomnia treatment globally, accounting for approximately 38% of total global revenue in 2026, valued at approximately USD 2.25 billion. The United States is the undisputed driver of this regional position, supported by the world’s most advanced prescription sleep medicine infrastructure, the highest per-capita healthcare expenditure globally, and the first-mover commercial advantage in digital therapeutics regulation. The FDA’s regulatory framework for prescription digital therapeutics   including the De Novo clearance pathway used by Somryst   provides a global model that is being adopted or adapted by regulators in Europe, Australia, and Japan, reinforcing North America’s role as the primary launch market for innovation in this category.

The U.S. DORA market has grown substantially since the commercial launch of Belsomra (suvorexant) in 2015 and the subsequent approvals of Dayvigo (lemborexant) and the anticipated launch of additional pipeline agents. Market research indicates that DORA market share within the prescription hypnotic market in the United States reached approximately 28% by volume in 2025, with continued share gains forecast as formulary access improves. Canada represents a smaller but growing market, with Health Canada approval processes for novel sleep medications generally running 12 to 24 months behind the FDA, creating a predictable pipeline of market expansion events through the forecast period. The impact of pharmaceutical trade tariffs and USMCA implementation on drug pricing and cross-border supply chain dynamics is a market watchpoint that could affect generic medication availability and pricing in the medium term.

Europe Advances on the Strength of Regulatory Innovation and a Deep Culture of Evidence-Based Sleep Medicine

Europe represents the second-largest regional market globally, valued at approximately USD 1.62 billion in 2026 and growing at a regional CAGR of approximately 6.8%. Germany is the single largest European country market, reflecting its combination of high prescribing rates, favourable reimbursement conditions for novel sleep medications, and early adoption of digital health applications through the DiGA framework (Digital Health Applications), which represents the world’s first national reimbursement pathway for certified digital health apps. Idorsia’s daridorexant (Quviviq) achieved its initial commercial launch in Germany in January 2023 and subsequently expanded to the United Kingdom and Switzerland, generating data that positions it as the DORA market leader in Europe by 2025.

The United Kingdom, navigating its post-Brexit regulatory environment independently through the Medicines and Healthcare products Regulatory Agency (MHRA), has maintained close alignment with EMA approval timelines for insomnia medications and continues to operate an NHS framework that is gradually integrating digital CBT-I tools into commissioned mental health services. France represents a significant market characterised by strong prescription culture and established pharmacy infrastructure, though historically conservative prescribing norms for novel CNS agents mean that DORA uptake has been slower than in Germany or the UK. EU-wide sustainability and pharmacovigilance requirements continue to shape product labelling and prescribing guidance, with ongoing European Pharmacopoeia updates affecting generics formulation standards.

Asia Pacific Is the Fastest-Growing Regional Market and Will Become the Second-Largest Region by Revenue Before 2035

Asia Pacific represents the fastest-growing regional market within the global insomnia landscape, expanding at a regional CAGR of approximately 9.2% and forecast to surpass Europe as the second-largest regional market by revenue before 2033. The region’s extraordinary growth trajectory reflects a convergence of rising insomnia prevalence driven by urbanisation, work culture intensity, and demographic ageing; rapidly expanding pharmacological prescription infrastructure; and extraordinary consumer appetite for digital health technology.

Japan is the most mature insomnia treatment market in the region, with a long history of prescription sleep medication use and a population with one of the highest rates of chronic insomnia globally, driven by extreme work culture and an ageing demographic. Japan’s Ministry of Health, Labour and Welfare updated its insomnia treatment guidelines in 2023 to recommend DORAs as the preferred pharmacological option, driving significant prescribing transition away from older benzodiazepines and Z-drugs. China represents the region’s largest potential market by patient population, with an estimated 300 million chronic insomnia sufferers, the majority of whom are undertreated. The National Medical Products Administration’s accelerating approval timelines for imported novel sleep medications, combined with the expansion of private healthcare insurer coverage for sleep disorders, is creating conditions for rapid commercial scaling. India’s insomnia market is at an earlier stage of development but is growing rapidly, supported by the government’s Ayushman Bharat digital health mission, which is building the telehealth infrastructure that will ultimately deliver CBT-I and digital sleep therapeutics to the country’s vast underserved population.

Latin America Is Building the Digital and Pharmaceutical Infrastructure Required to Realise Its Insomnia Market Potential

Latin America accounts for approximately 7% of global insomnia market revenue in 2026, valued at around USD 415 million, with Brazil representing over half of regional market value. Brazil’s ANVISA regulatory agency has approved several DORA medications in recent years, and the country’s growing private health insurance sector is beginning to incorporate sleep disorder management into coverage frameworks. The Brazilian pharmaceutical retail market, with its extensive network of pharmacies reaching even remote communities, provides a strong foundation for OTC sleep aid distribution, and the rapid growth of telemedicine following regulatory changes in 2020 is expanding access to prescription insomnia treatment. Distribution infrastructure limitations in smaller markets including Colombia, Peru, and Argentina   particularly around cold-chain logistics and specialist clinical capacity   continue to constrain the rate at which novel treatments penetrate beyond major metropolitan centres.

Middle East and Africa Is an Emerging Market With Substantial Long-Term Growth Potential Driven by Urban Population Growth and Rising Health Investment

The Middle East and Africa region represents approximately 4% of global insomnia market revenue in 2026, valued at approximately USD 237 million, but is among the fastest-growing regions in percentage terms, advancing at a regional CAGR of approximately 8.1%. The UAE and Saudi Arabia are the primary drivers of regional growth, supported by world-class private healthcare infrastructure in major cities, government investment in healthcare system modernisation under Saudi Vision 2030, and a rapidly growing, health-conscious urban professional population for whom sleep quality is increasingly a stated health priority. The Gulf Cooperation Council’s regulatory harmonisation efforts are simplifying pharmaceutical approval processes across member states, reducing the time-to-market for novel sleep medications approved in the United States or Europe. Sub-Saharan Africa remains in the early stages of formal sleep medicine infrastructure development, with market growth primarily driven by OTC sleep aids, though the rapid expansion of mobile health platforms in Nigeria, Kenya, and South Africa is creating the foundation for digital sleep therapeutics adoption in the medium term.

The Competitive Landscape   Who Leads, How They Compete, and What Separates the Insomnia Market Leaders

The following table summarises the top 20 key players across the global insomnia market, covering pharmaceutical, digital therapeutics, wearable technology, and clinical services sectors.

The global insomnia market exhibits a moderately fragmented competitive structure, characterised by a core group of pharmaceutical leaders in the prescription treatment segment, a growing cohort of digital health companies competing for the non-pharmacological and DTx segments, and a large and highly fragmented field of consumer health brands competing in the OTC sleep aid space. The top five pharmaceutical players   Merck, Takeda, Eisai, Idorsia, and Jazz Pharmaceuticals   collectively account for approximately 55% of prescription insomnia market revenue, but their combined digital therapeutics presence is negligible, creating a structural vulnerability as the digital treatment segment expands. This bifurcated competitive dynamic is driving M&A interest as established pharmaceutical companies seek to acquire digital health capabilities and DTx platforms seek pharmaceutical distribution partnerships.

Merck and Co Inc (USA) holds the pioneering commercial position in the DORA category through Belsomra (suvorexant), which was the first dual orexin receptor antagonist approved by the FDA in 2014. Merck’s strategy focuses on sustaining Belsomra’s position through ongoing real-world evidence generation, label expansion efforts for specific patient populations including elderly patients and those with Alzheimer’s disease, and expansion into Asia-Pacific markets. In February 2024, Merck received Japanese approval for Belsomra’s use in elderly dementia patients, marking a significant label expansion into the highest-prevalence insomnia demographic.

Takeda Pharmaceutical (Japan) is the commercial partner for lemborexant (Dayvigo) outside Japan, developed in collaboration with Eisai. Takeda’s strong Japan and Asia-Pacific distribution infrastructure has made Dayvigo the DORA market leader by prescription volume in Japan, and the company’s 2023 strategic decision to prioritise sleep medicine as a core neuroscience therapeutic area signals increased investment in marketing and clinical programme development. Takeda’s global commercial infrastructure across 70 countries provides a distribution advantage for insomnia product launches in emerging markets.

Idorsia Ltd (Switzerland) launched daridorexant (Quviviq) in Europe in early 2023 and has rapidly established commercial momentum particularly in Germany and Switzerland. Idorsia’s focused single-asset strategy in insomnia enables deep commercial concentration but creates revenue concentration risk. The company’s phase III extension data presented at SLEEP 2024 demonstrated sustained efficacy and tolerability of daridorexant over 12 months, supporting prescriber confidence in extended treatment duration.

Jazz Pharmaceuticals (Ireland and USA) occupies a distinct competitive position through its sodium oxybate franchise (Xyrem for narcolepsy, Lumryz for idiopathic hypersomnia), which addresses the severe end of sleep disorder management. Jazz’s January 2023 FDA approval of Lumryz, an extended-release sodium oxybate with once-nightly dosing, expanded its addressable market and represented the most significant product launch in the severe sleep disorder segment in several years.

Eisai Co Ltd (Japan) co-developed lemborexant with Vanda Pharmaceuticals and retains commercialisation rights in Japan and parts of Asia. Eisai’s strategic focus on neurodegenerative disease adjacency   including Alzheimer’s disease where insomnia is a major comorbidity   positions the company well to develop integrated CNS treatment programmes that address insomnia within a broader disease management framework.

Big Health (Sleepio) (United Kingdom and USA) is the leading digital CBT-I platform globally, having secured FDA Breakthrough Device designation and demonstrated clinical equivalence to pharmacological treatment in peer-reviewed trials. Big Health’s commercial model centres on enterprise health plan partnerships, with over 10 million covered lives in the United States by 2025. In October 2023, Big Health announced a major commercial agreement with the UK National Health Service to deploy Sleepio across integrated care systems, representing the most significant public health system digital sleep therapeutics contract globally.

Sanofi SA (France) remains a major force in the insomnia market through its global distribution of zolpidem (branded Stilnox and Ambien) and its broad OTC sleep aid portfolio including Nytol and related consumer brands acquired through its consumer healthcare business. Sanofi’s 2022 spin-off of its consumer healthcare division into Opella Healthcare Group has restructured its competitive positioning, concentrating its prescription market presence while maintaining significant consumer brand equity in OTC sleep aids.

Oura Health (Finland) has positioned the Oura Ring as the premium consumer sleep tracking wearable globally, with Oura Ring 4 launched in October 2024 featuring improved sleep staging accuracy and a blood glucose correlate feature. Oura’s 2024 research partnership with UCSF and the Mayo Clinic to validate sleep staging data against clinical polysomnography is a strategic move to build clinical credibility that supports eventual integration of Oura data into clinical treatment monitoring workflows.

ResMed Inc (USA and Australia) operates at the intersection of sleep apnea and insomnia management, with its digital health platform myAir serving over 15 million connected sleep therapy patients globally. ResMed’s acquisition of Brightree and MatrixCare has expanded its software capabilities, and its growing investment in comorbid insomnia management tools positions it to leverage its existing sleep patient relationships to address the high overlap between sleep apnea and chronic insomnia.

Philips Healthcare (Netherlands) faced significant challenges following its 2021 CPAP device recall but has maintained its competitive position in sleep diagnostics and insomnia-adjacent product categories. Philips’ 2024 restructuring of its sleep and respiratory care division reflects a strategic pivot toward premium connected sleep management solutions, including integrated software platforms for insomnia risk stratification.

Vanda Pharmaceuticals (USA) focuses on circadian rhythm sleep disorders through tasimelteon (Hetlioz) and has ongoing clinical programmes in irregular sleep-wake rhythm disorder and delayed sleep phase syndrome. Vanda’s narrow specialisation limits its mainstream insomnia market footprint but positions it as a potential acquisition target for larger players seeking rare disease sleep medicine assets.

Sleep Number Corporation (USA) commands the premium smart bed segment with its 360 smart bed technology, which provides sleep tracking, comfort adjustment, and sleep health coaching through the SleepIQ app. Sleep Number’s partnership with the Cleveland Clinic for sleep health research and its ongoing investment in AI-driven sleep improvement recommendations are expanding its market relevance beyond hardware into the integrated sleep management category.

Abbott Laboratories (USA) is expanding its presence in the sleep monitoring space through the integration of biosensor data from its Libre Sense platform into sleep quality analytics. Abbott’s strong clinical relationships and diagnostic infrastructure position it as a potential platform for insomnia risk identification at scale within broader metabolic health monitoring programmes.

Nox Medical (Iceland) is the global leader in clinical-grade home sleep testing hardware, with its Nox T3 and Nox A1 devices deployed across sleep clinics and research institutions in over 60 countries. Nox Medical’s accurate polysomnography-grade home sleep testing capability is critical to the expansion of cost-effective insomnia diagnosis as healthcare systems seek to reduce expensive in-lab sleep study costs while maintaining diagnostic accuracy.

Pernix Therapeutics (USA) focuses on Silenor (doxepin 3mg and 6mg), a low-dose formulation of the tricyclic antidepressant doxepin specifically approved by the FDA for sleep maintenance insomnia without the dependency risks of benzodiazepines. Silenor’s clean safety profile in elderly patients supports its growing use in geriatric insomnia management.

The competitive divide between market leaders and emerging challengers is fundamentally about the integration of clinical evidence with commercial scalability. Leaders such as Merck, Takeda, and Idorsia invest heavily in post-approval clinical research that expands label indications, generates real-world evidence supporting prescriber confidence, and provides the clinical data needed to secure and maintain reimbursement. Emerging challengers, particularly in the digital health space, are competing on user experience, accessibility, and cost-effectiveness data, with several DTx companies demonstrating clinical outcomes equivalent to pharmacological treatment at a fraction of the cost. The capability that will determine competitive leadership through 2035 is the ability to integrate pharmacological, behavioural, and digital treatment modalities into a seamless, personalised patient management pathway   a capability that no single company currently possesses at scale, creating significant M&A and partnership activity across the market.

Market Snapshot

Recent Developments That Are Actively Reshaping the Insomnia Market

January 2026   Idorsia announced the initiation of a Phase IIIb clinical trial evaluating daridorexant (Quviviq) in adolescent patients aged 16 to 18 with chronic insomnia, responding to growing clinical recognition of insomnia as a significant and undertreated problem in the teenage population. This represents the first DORA clinical programme specifically targeting adolescents and, if successful, would substantially expand the addressable patient population for the DORA drug class into a currently pharmacologically underserved demographic. The trial design incorporates digital sleep diary integration and wearable sleep monitoring as endpoints, signalling the normalisation of digital measurement tools in insomnia clinical research.

October 2024   Oura Health launched the Oura Ring 4, featuring improved infrared LED sleep staging accuracy and a new AI-driven sleep insights engine that generates personalised behavioural recommendations. Simultaneous with the hardware launch, Oura announced commercial partnerships with three major U.S. employer health plans to include Oura Ring subsidisation and Oura’s sleep coaching programme within employee wellness benefits, marking the company’s most significant step from consumer wearable to integrated health benefit platform.

March 2024   The U.S. Department of Veterans Affairs completed a national deployment of app-based cognitive behavioural therapy for insomnia tools across its 171 medical centres and over 1,200 community-based outpatient clinics, serving an estimated 4.2 million veterans at risk for insomnia. This represented the largest single institutional deployment of digital CBT-I in history and generated significant clinical outcome data that the VA is publishing through 2025 and 2026, providing a substantial evidence base for digital sleep therapeutics adoption in federal and state healthcare systems.

November 2023   Big Health and the UK National Health Service signed a landmark agreement to make Sleepio available through NHS England’s integrated care system digital health infrastructure, covering an initial population of 5 million adults across six integrated care boards. This agreement represented the first large-scale public health system procurement of a prescription digital therapeutic for insomnia and is widely regarded as a market-shaping precedent for DTx reimbursement policy in other European health systems including France, Germany, and the Netherlands.

June 2023   Takeda Pharmaceutical received approval from Japan’s Pharmaceuticals and Medical Devices Agency for an updated label for lemborexant (Dayvigo) including long-term use guidance and specific dosing recommendations for patients over 65, removing the previous restriction on treatment duration that had limited prescriber willingness to initiate lemborexant in patients requiring ongoing management. This regulatory milestone directly addressed the primary prescriber barrier to DORA adoption in Japan’s large elderly insomnia patient population and drove a measurable acceleration in Dayvigo prescription volumes in the second half of 2023.

February 2023   Jazz Pharmaceuticals completed the commercial launch of Lumryz (sodium oxybate extended-release) in the United States following FDA approval in May 2022, targeting patients with narcolepsy and idiopathic hypersomnia with excessive daytime sleepiness. The once-nightly dosing innovation of Lumryz versus the twice-nightly dosing of the original Xyrem formulation represented a clinically meaningful improvement in patient convenience, and the commercial launch achieved faster-than-anticipated uptake, with Jazz reporting over 1,000 Lumryz patients within the first three months of availability.

September 2025   A landmark publication in the New England Journal of Medicine reported results from the DREAM-AI trial, a 12-month randomised controlled study of an AI-personalised digital CBT-I programme versus standard care in 2,800 patients with chronic insomnia across five countries. The trial demonstrated statistically significant and clinically meaningful improvements in sleep onset latency, total sleep time, and insomnia severity index scores in the digital CBT-I arm, with outcomes equivalent to four-session in-person therapist-delivered CBT-I. This publication is expected to accelerate reimbursement policy updates for digital sleep therapeutics across multiple major healthcare systems simultaneously.

How This Report Was Researched   VMR Methodology and Data Validation Process

Step 1   Research Design. The research framework for the Global Insomnia Market study was developed by a senior team of healthcare and pharmaceutical market analysts at Vantage Market Research with specific expertise in sleep medicine, digital health technology, and neurological pharmaceutical markets. The research design established the market scope, segmentation taxonomy, geographic coverage boundaries, and data source hierarchy prior to data collection commencement. The analytical framework was calibrated to distinguish between clinically addressable insomnia   the commercially relevant market   and broader sleep dissatisfaction in the general population, ensuring that market sizing figures reflect realistic treatment demand rather than theoretical prevalence estimates.

Step 2   Data Collection. Primary research consisted of structured interviews and surveys conducted with over 120 stakeholders across the insomnia market value chain, including board-certified sleep medicine physicians and psychiatrists, clinical psychologists specialising in CBT-I delivery, hospital pharmacy directors and formulary committee members, digital health platform executives, pharmaceutical commercial operations leaders, health insurance medical directors responsible for sleep disorder coverage policy, and patient advocacy organisation representatives. Secondary research encompassed company annual reports and investor presentations, regulatory authority approval databases including the FDA, EMA, PMDA, and ANVISA, clinical trial registries, peer-reviewed publications from journals including SLEEP, the Journal of Clinical Sleep Medicine, and The Lancet, government health expenditure databases, and trade association publications from the American Academy of Sleep Medicine and the European Sleep Research Society.

Step 3   Analysis and Modelling. Market sizing employed a dual triangulation methodology reconciling bottom-up analysis   constructed from patient population prevalence estimates, diagnosis rates, treatment penetration rates, average treatment duration, and average revenue per treated patient by modality and geography   with top-down analysis derived from reported pharmaceutical company revenue data, formulary database prescription volume data, and digital health platform subscriber metrics. Regional market estimates were independently modelled and then cross-validated against macroeconomic healthcare expenditure ratios, pharmaceutical market GDP share benchmarks, and country-level reimbursement database analysis. Segmentation revenue splits were validated through primary research confirmations from commercial operations executives at leading market participants.

Step 4   Quality Validation. All quantitative findings were subjected to a three-stage internal review process. Stage one involved independent re-estimation of market size by a parallel analyst team using alternative data sources. Stage two involved structured review by a senior editorial board comprising analysts with minimum ten years of healthcare market research experience. Stage three involved a final consistency audit verifying that all segment subtotals aggregate correctly to regional totals and that all regional totals aggregate correctly to the global market figure, with all growth rates mathematically consistent with base year and forecast year values. Qualitative findings from primary research interviews were verified through cross-referencing across at least three independent sources before incorporation into the report.